AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03511638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon VISCOAT®
Description: Ophthalmic viscosurgical device
Study NCT02973646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir or Tenofovir
Description: Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
Study NCT02973646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2B
Study NCT02973646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2B
Study NCT04620057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cornstarch
Study NCT01508065 — intervention group
Intervention type: DEVICE
Intervention: Glucometer CGM-305
Description: The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
Study NCT00483743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 1020
Description: 250 mcg/caps 2 caps BID x 42 days
Study NCT01677611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol extract from Polygonum Cuspidatum
Description: Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
Study NCT01677611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03636594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
Study NCT01105338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Green tea drink
Description: Green tea drink
Study NCT01105338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea capsules
Description: green tea capsules
Study NCT00483743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 400mcg mcg capsules- 2 capsules BID
Study NCT01105338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Green tea placebo capsules
Description: Green tea placebo capsules
Study NCT01105338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene capsules
Description: Lycopene capsules
Study NCT03478423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: 30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study NCT03478423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study NCT03478423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study NCT01105338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lycopene placebo capsules
Description: Lycopene placebo capsules
Study NCT01105338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tomato rich diet
Description: Tomato rich diet
Study NCT04379518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT04379518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV
Study NCT04379518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study NCT06513780 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention were made.
Study NCT01588301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attending for cervical cytology
Description: A further invitation to attend for cervical cytology are going to be sent by mail to women
Study NCT01588301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kit for Self-collected vaginal sample
Description: Kit for self-collected vaginal sample are going to be directly sent at women's home
Study NCT01479049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP (moderate potassium) group
Description: Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
Study NCT01479049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP (High potassium) group
Description: Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
Study NCT04465487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6569
Description: Administered by intravenous (IV) infusion
Study NCT00483743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 caps BID x42 days
Study NCT00487422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 2 mg o.d.
Study NCT00487422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT00487422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study NCT04465487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered by IV infusion
Study NCT01331330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Normal DBS Programming
Study NCT01331330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Low Programming
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat was administered 3x week ( 2 weeks on 1 week off)
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was administered 2 x week ( 2weeks on 1 week off)
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib was administered 2 x week ( 2weeks on 1 week off)
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
Study NCT01023308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered 3x week ( 2 weeks on 1 week off)
Study NCT02294162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine i.v
Study NCT02294162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine i.v
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
Study NCT06781073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6297 (Part 1 - SAD)
Description: Single doses of CHF6297 at each period (for up to 3 periods per subject)
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1 - SAD)
Description: Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6297 (Part 2 - MAD)
Description: Twice daily doses of CHF6297 for 7 days
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2 - MAD)
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6297 (Part 3)
Description: Twice daily doses of CHF6297 for 14 days
Study NCT03688139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage Therapy
Description: Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice.
Study NCT03688139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
Study NCT00160875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride trihydrate
Description: Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
Study NCT00160875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
Study NCT04380753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Subjects will be enrolled and will receive AMG 510 PO QD.
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 3)
Description: Twice daily doses of placebo matching CHF6297 for 14 days
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6297 (Part 4)
Description: Twice daily doses of CHF6297 for 7 days
Study NCT06562101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Stromal Vascular Fraction Injection
Description: Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
Study NCT05990894 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
Study NCT02815488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 4)
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Study NCT03614975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax inactivated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
Study NCT03614975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone inactivated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
Study NCT01569464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine
Description: Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)
Study NCT01569464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)
Study NCT02468011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: vibration will be applied at 35 Hz
Study NCT04028661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed Modified Twin Block Appliance
Description: It is a functional appliance for mandibular advancement designed digitally on virtual models.
Study NCT01825954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RINCE
Description: The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
Study NCT01825954 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RINCE
Description: The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
Study NCT02631356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's lactate solution
Study NCT02631356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylated gelatin
Study NCT01390220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL261
Study NCT01390220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03301974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conjunctival autograft with fibrin glue
Description: Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
Study NCT03301974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sutured conjunctival autograft
Description: Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
Study NCT03301974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sutureless and glue-free conjunctival autograft
Description: Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
Study NCT03804073 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03804073 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study NCT02992132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Description: Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Study NCT02992132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 20 mg
Description: Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
Study NCT02992132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth
Study NCT03695874 — intervention group
Intervention type: OTHER
Intervention: Phase 1 : fill out 1 scale
Description: Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires.
Study NCT03695874 — intervention group
Intervention type: OTHER
Intervention: Phase 2 : fill out 1 scale and 4 questionnaires
Description: Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRV/COBI FDC
Description: A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF FDC
Description: A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D/C/F/TAF FDC - Matching Placebo
Description: Matching placebo of D/C/F/TAF FDC will be administered once daily.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF FDC Matching Placebo
Description: Matching placebo of FTC/TDF FDC will be administered once daily.
Study NCT02431247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC Matching Placebo
Description: Matching placebo of DRV/COBI FDC will be administered once daily.
Study NCT01046760 — intervention group
Intervention type: BEHAVIORAL
Intervention: Language Assessment
Description: Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
Study NCT02091674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Injected gel
Study NCT04365062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser and drug coated balloon
Description: Excimer laser and drug coated balloon
Study NCT04365062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser and plain balloon
Description: Excimer laser and plain balloon
Study NCT04365062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plain balloon and drug coated balloon
Description: plain balloon and drug coated balloon
Study NCT02914015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continous QLB (quadratus lumborum block)
Description: Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
Study NCT02914015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX50 Ultrasound Scanner
Description: The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan